Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.45 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.45 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.45 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.45 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.45 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.45 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.45 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.45 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | ANPEP | P15144 | 1/20 | 0.43 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.43 |
| ▸ | GABRP | O00591 | 1/20 | 0.43 |
| ▸ | GABRD | O14764 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2982918 | 0.98 | ALOX15 (0.56) | ALOX15TSHRCYP2D6EPHX1EPHX2 | |
| SCHEMBL20659995 | 0.92 | CYP2D6 (0.56) | ALOX15TSHRCYP2D6EPHX1EPHX2 | |
| SCHEMBL856745 | 0.88 | SLC6A1 (0.57) | ALOX15TSHRCYP2D6EPHX1EPHX2 | |
| SCHEMBL2836599 | 0.88 | SLC6A1 (0.57) | ALOX15TSHRCYP2D6EPHX1EPHX2 | |
| SCHEMBL2832801 | 0.88 | SLC6A1 (0.57) | ALOX15TSHRCYP2D6EPHX1EPHX2 | |
| SCHEMBL22389604 | 0.87 | CYP2D6 (0.53) | ALOX15TSHRCYP2D6EPHX1EPHX2 | |
| Bromide SCHEMBL23881409 | 0.86 | SLC6A1 (0.55) | ALOX15TSHRCYP2D6EPHX1EPHX2 | |
| Hydrochloric Acid SCHEMBL15662845 | 0.86 | SLC6A1 (0.55) | ALOX15TSHRCYP2D6EPHX1EPHX2 | |
| Hydrochloric Acid SCHEMBL3830642 | 0.86 | SLC6A1 (0.55) | ALOX15TSHRCYP2D6EPHX1EPHX2 | |
| SCHEMBL4396572 | 0.84 | CYP2D6 (0.63) | ALOX15TSHRCYP2D6EPHX1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 388 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025049555-A1 | COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL | OERTH BIO LLC (US) | 2025-03-06 | — | — | WO | disclosed |
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| WO-2024130408-A1 | CONJUGATES COMPRISING ANTIFUNGALS AND CASEIN KINASE (CK1) INHIBITORS AND METHODS OF USE THEREOF | BRIGHT ANGEL THERAPEUTICS INC. (CA) | 2024-06-27 | — | — | WO | disclosed |
| EP-4384520-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | Uppthera, Inc. (KR) | 2024-06-19 | — | — | EP | disclosed |
| EP-4380575-A1 | DRUG CONJUGATES OF SUGAR DERIVATIVES AND USES THEREOF AS SENOLYTIC AGENTS | Rubedo Life Sciences, Inc. (US) | 2024-06-12 | — | — | EP | disclosed |
| WO-2024117789-A1 | PLK1 DEGRADATION INDUCING COMPOUNDS WITH INCREASED RIGIDITY | UPPTHERA, INC. (KR) | 2024-06-06 | — | — | WO | disclosed |
| EP-4377307-A1 | COMPOUNDS FOR THE TREATMENT OF PAIN, IN PARTICULAR NEUROPATHIC PAIN, AND/OR OTHER DISEASES OR DISORDERS THAT ARE ASSOCIATED WITH AT2R AND/OR AT2R MEDIATED SIGNALING | Confo Therapeutics N.V. (BE) | 2024-06-05 | — | — | EP | disclosed |
| EP-4374157-A2 | FRET-BASED ASSAYS | The General Hospital Corporation (US) | 2024-05-29 | — | — | EP | disclosed |
| US-11981685-B2 | Bicyclic heterocyclyl derivatives as IRAK4 inhibitors | AURIGENE ONCOLOGY LIMITED (IN) | 2024-05-14 | — | — | US | disclosed |
| EP-4363415-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | Tecnimede, Sociedade Técnico-Medicinal, SA (PT) | 2024-05-08 | — | — | EP | disclosed |
| WO-2002051831-A1 | OXYBENZAMIDES DERIVATIVES AS FACTOR XA INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-07-04 | — | — | WO | disclosed |
| EP-1217000-A1 | Inhibitors of factor Xa and factor VIIa | Aventis Pharma Deutschland GmbH (DE) | 2002-06-26 | — | — | EP | disclosed |
| US-5763604-A | ANTICOAGULANTS | HOFFMANN-LA ROCHE INC. (US) | 1998-06-09 | — | — | US | disclosed |
| US-5677448-A | CHEMICAL INTERMEDIATES FOR MAKING ANTAGONIST OF THROMBIN, TREATING THROMBOSIS, STROKE, INFLAMMATION, ARTERIOSCLEROSIS, CARDIOVASCULAR DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 1997-10-14 | — | — | US | disclosed |
| US-5578594-A | ANTICOAGULANTS | HOFFMANN-LA ROCHE INC. (US) | 1996-11-26 | — | — | US | disclosed |
| EP-0520882-B1 | 2-Aminopyrimidin-4-carboxamide derivatives, their preparation and their application in therapy | SYNTHELABO (FR) | 1995-07-12 | — | — | EP | disclosed |
| US-5405854-A | Anticoagulants | HOFFMANN-LA ROCHE INC. (US) | 1995-04-11 | — | — | US | disclosed |
| CN-1076690-A | SULFONAMIDOCARBOXAMIDES | HOFFMANN LA ROCHE (CH) | 1993-09-29 | — | — | CN | disclosed |
| EP-0522914-A1 | 2-Piperidinylpyrimidin-4-carboxamide derivatives, their preparation and their application in therapy | SYNTHELABO (FR) | 1993-01-13 | — | — | EP | disclosed |
| EP-0520882-A1 | 2-Aminopyrimidin-4-carboxamide derivatives, their preparation and their application in therapy | SYNTHELABO (FR) | 1992-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11981685-B2 | Bicyclic heterocyclyl derivatives as IRAK4 inhibitors | IRAK4, IRAK3, IRAK1 | ALOX15 4201/4885TSHR 4307/4885CYP2D6 2396/4885 |
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | USP1, UBA1, UBXN1 | ALOX15 3880/4885TSHR 3937/4885CYP2D6 2800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.